AP9701148A0 - Dimesylate salts of neuropeptide Y ligands. - Google Patents

Dimesylate salts of neuropeptide Y ligands.

Info

Publication number
AP9701148A0
AP9701148A0 APAP/P/1997/001148A AP9701148A AP9701148A0 AP 9701148 A0 AP9701148 A0 AP 9701148A0 AP 9701148 A AP9701148 A AP 9701148A AP 9701148 A0 AP9701148 A0 AP 9701148A0
Authority
AP
ARIPO
Prior art keywords
neuropeptide
ligands
dimesylate
salts
dimesylate salts
Prior art date
Application number
APAP/P/1997/001148A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
Lyle R Brostrom
Alireza S Kord
Laurie A Whipple
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701148A0 publication Critical patent/AP9701148A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001148A 1996-11-26 1997-11-20 Dimesylate salts of neuropeptide Y ligands. AP9701148A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3181596P 1996-11-26 1996-11-26
PCT/IB1997/001465 WO1998023603A1 (en) 1996-11-26 1997-11-19 Dimesylate salts of neuropeptide y ligands

Publications (1)

Publication Number Publication Date
AP9701148A0 true AP9701148A0 (en) 1998-01-31

Family

ID=21861551

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001148A AP9701148A0 (en) 1996-11-26 1997-11-20 Dimesylate salts of neuropeptide Y ligands.

Country Status (23)

Country Link
US (1) US5914329A (enExample)
EP (1) EP0944611B1 (enExample)
JP (1) JP3120861B2 (enExample)
AP (1) AP9701148A0 (enExample)
AR (1) AR010304A1 (enExample)
AT (1) ATE257472T1 (enExample)
AU (1) AU4792497A (enExample)
BR (1) BR9713538A (enExample)
CA (1) CA2272927C (enExample)
DE (1) DE69727155T2 (enExample)
DK (1) DK0944611T3 (enExample)
ES (1) ES2213207T3 (enExample)
GT (1) GT199700123A (enExample)
HN (1) HN1997000154A (enExample)
HR (1) HRP970640A2 (enExample)
ID (1) ID18964A (enExample)
MA (1) MA26450A1 (enExample)
PA (1) PA8441701A1 (enExample)
PE (1) PE17099A1 (enExample)
PT (1) PT944611E (enExample)
TN (1) TNSN97191A1 (enExample)
WO (1) WO1998023603A1 (enExample)
ZA (1) ZA9710587B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001232900A1 (en) * 2000-01-20 2001-07-31 Michael Amling Methods and compositions for control of bone formation via modulation of neuropeptide y activity
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
NZ533848A (en) 2002-01-09 2006-11-30 Arexis Ab Detection of mutations in the flavin-containing monooxygenase (FMO3) gene
EP1701722B1 (en) * 2004-11-23 2009-10-14 Dong Wha Pharmaceutical Co., Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy¨]pentoxy}benzamidine 2 methansulfonic acid salt
EP1877076A4 (en) * 2005-04-15 2012-02-01 Regenertech Pty Ltd USE OF NEUROPEPTIDES Y (NPY) AND AGONIST OF ANTAGONISTS THEREOF FOR REGENERATING TISSUES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK57097A3 (en) * 1994-11-07 1998-10-07 Pfizer Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Also Published As

Publication number Publication date
ES2213207T3 (es) 2004-08-16
ATE257472T1 (de) 2004-01-15
AU4792497A (en) 1998-06-22
JP3120861B2 (ja) 2000-12-25
GT199700123A (es) 1999-05-19
JP2000505110A (ja) 2000-04-25
ID18964A (id) 1998-05-28
PA8441701A1 (es) 2000-05-24
CA2272927A1 (en) 1998-06-04
MA26450A1 (fr) 2004-12-20
DE69727155D1 (de) 2004-02-12
CA2272927C (en) 2003-02-04
PE17099A1 (es) 1999-02-19
DK0944611T3 (da) 2004-04-13
TNSN97191A1 (fr) 2005-03-15
US5914329A (en) 1999-06-22
DE69727155T2 (de) 2004-07-08
HRP970640A2 (en) 1998-10-31
BR9713538A (enExample) 2000-03-21
HN1997000154A (es) 1999-02-09
ZA9710587B (en) 1999-05-25
AR010304A1 (es) 2000-06-07
PT944611E (pt) 2004-04-30
EP0944611B1 (en) 2004-01-07
WO1998023603A1 (en) 1998-06-04
EP0944611A1 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
PL316658A1 (en) Novel application of serotonin antagonists
NO970162D0 (no) Substituerte pyrimidinforbindelser og anvendelse derav
DE69526206D1 (de) Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit
BG101112A (bg) Използване на хетероциклени съединения
TW290443B (enExample)
DK0464558T3 (da) Antimigræne-alkoxypyrimidinderivater
DE69941154D1 (de) Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
IL118167A0 (en) Pyrazolo (1,5a) pyrimidines their preparation and use
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
PL340467A1 (en) Application of mithrazapin in treating apnoea dissomnia
IL150125A0 (en) Novel compounds
FI971127A7 (fi) 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollagee nin kypsymis- ja rakentumishäiriöiden hoitamiseen
AP9701148A0 (en) Dimesylate salts of neuropeptide Y ligands.
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
PT828851E (pt) Inibidores de tripeptidilpeptidase
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
DE69518438D1 (de) Behandlung von übereregten nervenzellenfunktionen
AP2000001963A0 (en) Paroxetine ascorbate.
FI965171A7 (fi) Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö ka svainten hoidossa sivuvaikutuksien vähentämiseksi
EP0210099A3 (en) Use of n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamide in the treatment of parkinsons's disease
ECSP972321A (es) Sales dimesilato de los ligandos del neuropeptido y antecedentes de la invencion
DE69905731D1 (de) Analgetische verwendung von podophylotoxin zur schmerzbehandlung der weiblichen genitalorgane
MX9706424A (es) Uso de la moxonidina para el tratamiento de la aterosclerosis.